Form D · Biotechnology
DVS Sciences, Inc.
Richmond Hill, A6 · CIK 0001512982
Offering snapshot reported Feb 16, 2011 · SEC filing
- Reported sold
- $4.13M Offering amount: $14.8M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 20, 2010 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 16, 2011 | Initial | $4,131,828 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-155425
Series A-1 Preferred Stock and Series A-2 Preferred Stock, including the shares of Common Stock issuable upon conversion of the Series A-1 and Series A-2 Preferred Stock.
Source: Form D, filed Feb 16, 2011. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| William Burkoth | Director |
| Garry Nolan | Director |
| Neil Reid | Director |
| Andrew J. Schwab | Director |
| Scott Tanner | Director, Executive |
| Frank Witney | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
70 Peninsula Crescent
Richmond Hill, A6, L4S 1Z5
Richmond Hill, A6, L4S 1Z5